Crossmark

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

Crossref DOI link: https://doi.org/10.1007/s11864-018-0532-2

Published Online: 2018-03-08

Published Print: 2018-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Laneuville, Pierre
License Information

Text and Data Mining valid from 2018-03-01
More Information

Article History

First Online: 8 March 2018

Compliance with Ethical Standards

:

: Pierre Laneuville has received research support for clinical trials through grants from Ariad, Bristol-Myers Squibb, and Novartis; has received compensation for participation on advisory boards for Bristol-Myers Squibb, Novartis, and Pfizer; has received compensation from Novartis for service as a consultant; and has received honoraria for presentations at medical meetings invited and supported by Bristol-Myers Squibb and Novartis.

: This article does not contain any studies with human or animal subjects performed by any of the authors.